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Abstract  32 
Dietary fat has been implicated in the rise of obesity due to its energy density, palatability and weak 33 
effects on satiety. As fat is a major contributor to overall energy intake, incorporating fat with 34 
satiating properties could potentially reduce energy intake. This review outlines the potential 35 
mechanisms, as far as we know, by which Medium-Chain Triglycerides (MCT), Conjugated 36 
Linoleic Acid (CLA), Short-Chain Fatty Acids (SCFA), Diacylglycerol (DAG), n-3 PUFA, and 37 
Small Particle Lipids, exerts their satiating effects. The evidence suggests that the lipid with the 38 
most potential to enhance satiety is MCT. SCFA can also promote satiety, but oral administration 39 
has been linked to poor tolerability rather than satiety. Data on the appetite effects of CLA is limited 40 
but does suggest potential. Research comparing these lipids to each other is also lacking and should 41 
be explored to elucidate which of these ‘functional lipids’ is the most beneficial in enhancing 42 
satiety. 43 
 44 
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Introduction 57 
The continual growth of global obesity is well documented (WHO 2000), as is the concomitant rise 58 
of comorbidities such as type 2 diabetes, various cancers and cardiovascular disease (Guh et al. 59 
2009). The main driver of weight gain is a positive energy balance, where an individual consumes 60 
more energy than they expend, for a prolonged period. The current obesogenic environment we live 61 
in can promote obesity due to the large volume of time spent sedentary (Deforche et al. 2015; Dong, 62 
Block, and Mandel 2004) as well as increases in the energy density (Stelmach-Mardas et al. 2016), 63 
portion size (Ello-Martin, Ledikwe, and Rolls 2005) and relative cost (Drewnowski and Darmon 64 
2005) of food, all promoting overconsumption. Dietary fat has also been implicated in the rise of 65 
obesity due to its energy density, palatability and weak effects on satiety (Blundell et al. 1993;  66 
Blundell and MacDiarmid 1997).  67 
Appetite is the internal driving force for the search, choice and ingestion of food (De Graaf et al. 68 
2004). Humans eat in episodes consisting of either meals or snacks (Gibney and Wolever 1997). 69 
The way in which food intake is controlled is described within the satiety cascade (Blundell, 70 
Rogers, and Hill 1987). Satiation occurs during the course of eating and eventually brings the 71 
period of eating to an end. Satiety occurs after the end of an eating episode and is the situation in 72 
which initiation of further eating is inhibited (Blundell et al. 2010). Calorie restriction is a common 73 
method employed by individuals trying to achieve weight loss (Das et al. 2007). The lack of success 74 
of many of these calorie-restricted diets lies in the individual’s failure to adhere to the diet 75 
(Heymsfield et al. 2007),  due to feelings of intense hunger, constant thoughts of food, and 76 
emotional changes; all of which can culminate in temptations to break the diet (Franklin et al. 77 
1948). Foods or ingredients with the potential to enhance satiety could be beneficial in augmenting 78 
the success of calorie restricted diets, by decreasing the adverse effects associated with low energy 79 
intake and prolonging the feeling of fullness (Chambers, McCrickerd, and Yeomans 2015). Indeed, 80 
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results have shown that consumers are willing to try satiety-promoting foods and that many would 81 
also prefer a greater amount of foods with this functional element (Hetherington et al. 2013).  82 
Although dietary fat can lead to passive overconsumption (Green et al. 2000), there is a growing 83 
body of research which suggests that some fats may elicit stronger satiety responses than others. 84 
These fats may not be able to match the satiating properties of protein or carbohydrate on an 85 
isocaloric basis (Blundell and MacDiarmid 1997); however given that fat should make up to 35% of 86 
energy intake (Department of Health 1984) and some obese individuals have reported intakes 87 
exceeding 40% (Dreon et al. 1988), incorporating lipids with satiating properties has the potential to 88 
reduce overall energy intake. Data investigating lipids with satiating properties is still inconclusive.  89 
The purpose of this review is to highlight fat with the potential to promote satiety in humans, the 90 
mechanisms by which they work and to evaluate which has the greatest potential to be utilised in 91 
weight management strategies. We discuss the potential role and mechanisms of medium chain 92 
triglycerides, conjugated linoleic acid, short-chain fatty acids, diacylglycerol, omega-3 93 
polyunsaturated fatty acids, and small particle lipids on satiety, satiation and perceptions of these. 94 
Acute research refers to studies which examine the transient effect of dietary lipids, usually a single 95 
bolus, whereas chronic adaptation refers to the study of a dietary lipid administered over two or 96 
more days. Studies were included that focused on satiety, satiation, perceived satiety or satiation (i.e 97 
visual analogue scales) or included elements that allowed for speculation into the effects of satiety 98 
(i.e. energy intake). This allowed for discussion into the potential role of a lipid where limited 99 
research is currently available. Due to the production of SCFA in the gut, both ‘direct’ and 100 
‘indirect’ studies are included; the direct administration of SCFA in a vehicle, or indirectly via 101 
insoluble fibre which is fermented in the gut. Where possible, human studies are included, but 102 
where mechanistic data in human studies are missing, animal studies are discussed.  103 
 104 
Medium-Chain Triglycerides  105 
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Medium-Chain Triglycerides (MCT) are triglycerides (esters derived from glycerol and three fatty 106 
acids) with fatty acid chain lengths of 6-12 carbon atoms. These include: capronic acid (C6:0), 107 
caprylic acid (C8:0), capric acid (C10:0) and lauric acid (C12:0). Along with synthetically produced 108 
oils, MCTs are found naturally in coconut oil, palm kernel oil, and a small amount in dairy fat 109 
(Marten, Pfeuffer, and Schrezenmeir 2006). According to the 2014 report on nutrient intake in the 110 
U.S, approximately 1.8% of all fat is MCFA (Agriculture 2014). However, due to a growing global 111 
popularity for coconut oil, this is likely to have increased. 112 
 113 
Mechanisms of Satiety  114 
MCT have been proposed to affect satiety by a number of mechanisms which may be cumulative. 115 
Outlined below are some of the possible mechanisms. 116 
Absorption 117 
In 1951, Bloom, Chaikoff, and Reinhardt (1951) tested absorption rates of different 14C labelled 118 
acids and found that lauric acid and capric acid (both medium chain fatty acids) are transported via 119 
the portal venous system, unlike long-chain triglycerides (LCT) which are transported by the 120 
lymphatic system. This method of absorption is faster and more efficient than triglycerides with a 121 
longer chain. Further, the esterification of MCT is limited, resulting in high levels of oxidation to 122 
the point of MCT behaving more like glucose than fat (Marten, Pfeuffer, and Schrezenmeir 2006). 123 
The results of Van Wymelbeke and colleagues (Van Wymelbeke, Louis-Sylvestre, and Fantino 124 
2001) and Rolls et al. (Rolls et al. 1988) indicate pre-absorptive mechanisms pertaining to the rapid 125 
rate of absorption of MCT. Where LCT result in two ‘peaks’ of absorption; that being at the initial 126 
point of ingestion and a second delayed peak at the beginning of the next meal (Fielding et al. 1996; 127 
Evans et al. 1988; Cohn et al. 1988), MCT are fully absorbed at the point of ingestion. Therefore, 128 
MCT may contribute to satiation by this ‘full absorption’ mechanism.  129 
 130 
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 Substrate Oxidation 131 
Fatty acid oxidation has been linked with increased satiety  (Langhans and Scharrer 1987; Friedman 132 
et al. 1999). MCT may have an anorexigenic effect through the concomitant production of ketones 133 
that is a result of increased acetyl-CoA influx (Tsuji et al. 2001). Ingestion of MCT has been shown 134 
to lead to increased concentrations of the ketone body β-hydroxybutyrate (Page et al. 2009), which 135 
is thought to suppress appetite (Laeger, Metges, and Kuhla 2010; Scharrer 1999). The increase in 136 
ketone bodies provides a substrate for energy, thereby sparing glucose (Zhang et al. 2013) and 137 
decreasing food intake (Mayer 1953).  138 
 139 
 Satiety Hormones 140 
Few papers have examined the response of these satiety hormones to MCT consumption (Maas et 141 
al. 1998; Barbera et al. 2000; M-P St-Onge et al. 2014). Cholecystokinin (CCK) was the first gut 142 
hormone found to influence satiety (Gibbs, Young, and Smith 1973). Lipid ingestion is linked to the 143 
secretion of CCK, however this is dependent on the fatty acid chain length. The majority of MCT 144 
do not lead to increased CCK levels (McLaughlin et al. 1999; Beglinger et al. 2010). However, in a 145 
study by McLaughlin and colleagues (McLaughlin et al. 1999) CCK was released after either 146 
emulsions of capric (C10) or lauric (C12) acid were infused into the gut of healthy volunteers. The 147 
control lipid in that study was Tween 80 mixed with a phosphate-buffered saline, which also 148 
increased CCK secretion above baseline, meaning that the increase observed by C10 was not 149 
significant. Feltrin and colleagues (Feltrin et al. 2004) aimed to address this limitation by using an 150 
appropriate control and found that both C12 and C10 lead to increased CCK release, although the 151 
magnitude of this increase was greater with C12. Further, C12 significantly decreased perceptions 152 
of hunger, desire to eat, and prospective food consumption as well as energy intake at an ad libitum 153 
buffet meal, whereas C10 did not. This suggests that even though some fatty acids with chain 154 
lengths below 12 cause secretion of CCK, this is unlikely to affect appetite sensation. Multiple 155 
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studies confirm that fatty acids with chain lengths of 12 and above are able to stimulate CCK, 156 
whereas chain lengths of 10 and below are not as effective (D Matzinger et al. 2000; J. T. 157 
McLaughlin et al. 1998; Feltrin et al. 2007, 2006; Feinle et al. 2001; Lal et al. 2004; French et al. 158 
2000). Furthermore, despite  initial findings suggesting otherwise (Hildebrand et al. 1990), CCK 159 
receptor antagonist studies indicate no role of CCK in fat induced satiety (Drewe et al. 1992). 160 
Despite the controversial role of CCK, it is still widely reported that CCK is a mediator of fat-161 
related satiety, through a delaying of gastric emptying (Liddle et al. 1986; Daniel Matzinger et al. 162 
1999) by modulation of antropyloroduodenal motility (Feltrin et al. 2004), and a reduction of the 163 
capacity that can be tolerated in the upper gastrointestinal (GI) tract (Lal et al. 2004); processes 164 
which rely on the digestion of triglycerides into free fatty acids (Feinle et al. 2001; D Matzinger et 165 
al. 2000; Feinle et al. 2003; Pilichiewicz et al. 2003). Therefore as MCT do not require bile salts, 166 
secreted by CCK, for emulsification (McLaughlin et al. 1999), this could explain the lack of CCK 167 
response by shorter chain fatty acids. Despite this, MCT do seem to have appetite-suppressing 168 
effects, which are independent of CCK.  169 
 170 
PYY is a 36 amino acid peptide belonging to the pancreatic polypeptide family, and its secretion is 171 
initiated by the sensing of nutrients, primarily protein (Batterham et al. 2006) and fat (Aponte et al. 172 
1985; Pironi et al. 1993), in the GI lumen. Its anorectic effect has been demonstrated via peripheral 173 
administration of PYY3-36, which increases c-fos expression in the arcuate nucleus (ARC); and 174 
direct injection into the ARC inhibits food intake in rats and mice (Batterham et al. 2002; Riediger 175 
et al. 2004). After administering intraduodenal infusions of LCFA (corn oil) or MCT (56% octanoic 176 
acid and 43% decanoic acid), Maas et al. (Maas et al. 1998) found that MCT did result in PYY 177 
secretion, but not to the same extent as LCT. However, the caloric load of each infusion differed; 178 
11.6 kJ·min from MCT and 22.7 kJ·min from LCFA which may have affected the potential for 179 
PYY release. C10 has also been shown to stimulate PYY secretion in a dose-dependent manner 180 
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(Feltrin et al. 2007). It must be noted that CCK is a potent stimulator of PYY secretion (Marie-181 
Pierre St-Onge and Jones 2002), which could explain the weaker release of PYY by MCT. To date 182 
no study has investigated MCT alongside PYY receptor antagonists, which could provide 183 
conclusive information as to the effects of MCT on PYY release (St-Onge et al. 2014). 184 
A more recent pilot study in overweight men investigated MCT ingested orally (as opposed to these 185 
aforementioned studies which utilised duodenal infusions) on a variety of gut peptide hormones, 186 
and found that, compared to LCT, MCT did not affect total ghrelin or GLP-1; but leptin and PYY 187 
concentrations remained higher after the MCT meal (St-Onge et al. 2014). However, correlations 188 
between these results and food intake at the ad libitum meal provided were opposite to the expected 189 
direction, suggesting that the MCT suppression of food intake is not mediated by gut peptide 190 
hormones. While these results do not appear to show a link between gut peptides and MCT driven 191 
satiety, there is clearly more work to be done to confirm this.  192 
 193 
 Other Considerations 194 
MCFA are considered unpalatable, and if initially digested in the mouth MCT may play a role in 195 
sensory specific satiation (Clegg 2010). As well as their unpalatability, MCT have been shown to 196 
cause GI distress, including vomiting and cramping (Jeukendrup et al. 1998; Goedecke et al. 2005). 197 
This has been shown at high dosages of up to 85g, which are not typically used in appetite research; 198 
more so sports performance (Jeukendrup et al. 1998). Infusion studies have reported greater nausea 199 
after LCT than MCT (Barbera et al. 2000; Feinle et al. 2001), which is not supported by more 200 
recent findings that nausea was greatest after a breakfast containing MCT (Coleman, Quinn, and 201 
Clegg 2016). Regardless, this must be considered to ensure that any effects on satiety are not a 202 
result of GI distress. 203 
 204 
Effect of acute intake of medium chain triglycerides on satiety 205 
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Acute studies examining the effect of MCT on satiety and energy balance appear to have equivocal 206 
findings. Some studies have found reductions at ad libitum meals following intake of MCT (Rolls et 207 
al. 1988; Van Wymelbeke, Louis-Sylvestre, and Fantino 2001; Van Wymelbeke et al. 1998); 208 
whereas others have reported no effect (Barbera et al. 2000; Poppitt et al. 2010). There are 209 
limitations in several studies reporting no effect of MCT on satiety which suggests there is potential 210 
for MCT to increase satiety. In the first study to investigate the effect of MCT on satiety in humans, 211 
Rolls et al. (1988) administered three doses of either MCT or LCT (100, 200 and 300 kcal) in 212 
beverage form and examined the effect on food intake at an ad libitum meal in dieters and non-213 
dieters. In dieters, they found no consistent change in intake. However, in non-dieters there was an 214 
overall decrease of ~14% in energy intake after MCT, and this was dose-dependent. Similarly, Van 215 
Wymelbeke et al. (1998) found that MCT led to decreased intake at lunch when it was added to a 216 
carbohydrate breakfast. Furthermore, in a later study by the same research group, there was 217 
decreased intake at dinner after an MCT lunch when compared to a lunch with either LCT, 218 
carbohydrate or a fat substitute (Van Wymelbeke, Louis-Sylvestre, and Fantino 2001). However, 219 
Poppit et al. (2010) report no influence of MCT on perceived satiety after 18 healthy men 220 
consumed high-fat breakfasts containing short-chain triglycerides, MCT or LCT. This could be 221 
explained by the small dose of MCT in that study (10g), whereas previous studies have observed 222 
significant results with doses of 20 g or more (St-Onge et al. 2014; Rolls et al. 1988; Van 223 
Wymelbeke, Louis-Sylvestre, and Fantino 2001; Van Wymelbeke et al. 1998).  224 
 225 
As aforementioned, adverse effects related to MCT ingestion may confound any purported satiety 226 
effects. Therefore, this must be either considered when analysing results or, preferably, when 227 
designing the vehicle for the lipids. The studies of Poppit and colleagues (2010) and Van 228 
Wymelbeke and colleagues (1998) both administered visual analogue scales to examine if there 229 
were any subjective sensory differences between the meals provided and found that there was no 230 
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difference, concluding that any effects were not related to palatability. A later study by Van 231 
Wymelbeke’s group (Van Wymelbeke, Louis-Sylvestre, and Fantino 2001) along with the study by 232 
Rolls’ research group (Rolls et al. 1988) included a pre-test where palatability of the test meals were 233 
assessed; participants who registered low palatability scores were excluded in Rolls’ study, whereas 234 
the preliminary screening indicated participants were unable to distinguish between the breakfasts 235 
in the study by Van Wymelbeke. 236 
 237 
Effects on satiety of chronic consumption of medium chain triglycerides 238 
There are few long-term studies reporting the effects of MCT on satiety, though many have studied 239 
weight loss effects primarily through diet-induced thermogenesis. However, this is outside the 240 
scope of this review. Krotkiewski (2001) examined extreme hypocaloric diets combined with either 241 
MCT or LCT in overweight women. Weight loss was accelerated in the MCT group for the first two 242 
weeks; however this decreased in weeks 3 and 4. This pattern was also observed in perceived 243 
appetite and satiety, as after the first two weeks perceived appetite was lower at all time points and 244 
perceived postprandial satiety was higher. The difference between the groups diminished by week 245 
4, perhaps indicating an adaptation to chronic MCT intake. However, it must be noted that the 246 
amounts of each fat provided in this study were very low (9.9g of MCT and 8.8g of LCT). 247 
Therefore if MCT has an effect at such low doses there is a rationale to increase the dose after the 248 
initial adaptation has taken place. The results of this study (Krotkiewski 2001) show some exciting 249 
potential as the decreased feelings of hunger may aid weight loss program adherence by reducing 250 
dropout rates.251 
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Conjugated linoleic acid 252 
Conjugated linoleic acid (CLA) is the name of a family of stereo and positional isomers of 253 
octadecadienoic acid (linoleic acid), meaning isomers with the same formula and constitution but 254 
different structures. ‘Conjugated’ refers to the conjugated double bonds, in that they are only 255 
separated by one single bond. Of the 24 isomers of CLA (Kreider et al. 2010), the most commonly 256 
examined in research are the cis-9, trans-11 CLA isomer, and the trans-10, cis-12 CLA isomer 257 
(Campbell and Kreider 2008). The richest sources of these isomers are  meat and dairy derived from 258 
ruminants, of which approximately 90% is the cis-9, trans-11 isomer and the remaining 10% is the 259 
trans-10, cis-12 isomer (Mushtaq, Heather Mangiapane, and Hunter 2010; Kennedy et al. 2010). 260 
Commercially available CLA typically contain approximately equal amounts of the cis-9, trans-11 261 
and the trans-10, cis-12 isomers (Hargrave et al. 2002; Norris et al. 2009).  262 
 263 
Mechanisms of Satiety  264 
CLA effects on body weight and body composition have been widely reported (Blankson et al. 265 
2000; Belury, Mahon, and Banni 2003; Gaullier et al. 2007, 2005). CLA is thought to reduce the 266 
size of adipocytes through stimulation of pro-inflammatory cytokines such as TNFα (tumour 267 
necrosis factor α) and by the inhibition of PPARγ (peroxisome proliferator-activated receptors) 268 
receptors by inhibiting adipocyte differentiation (Salas-Salvadó, Márquez-Sandoval, and Bulló 269 
2006; Cawthorn and Sethi 2008).  The trans-10, cis-12 isomer is reported to exert the most anti-270 
adipogenic effects through decreased expression of genes which regulate triglyceride storage and 271 
transport of fatty acids (Brown and McIntosh 2003).  272 
 273 
Although CLA has received little attention to date in relation to satiety, it does also have the 274 
potential to reduce energy intake. Despite many not human studies specifically examining food 275 
intake following CLA consumption, various animal studies have shown a decrease in intake after 276 
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administration of CLA (Cao et al. 2007; Hargrave et al. 2002; Miner et al. 2001; Santora, 277 
Palmquist, and Roehrig 2000; Yeonhwa Park et al. 1997; R Dugan et al. 1997), although some 278 
studies found no effect (Tsuboyama-Kasaoka et al. 2000; DeLany et al. 1999; Wong et al. 1997). 279 
Furthermore, even when decreased food intake was observed, the reductions do not completely 280 
explain decreases in body fat (Shelton et al. 2012; Hargrave et al. 2002; Y. Park et al. 2007; Miner 281 
et al. 2001), suggesting favourable changes in body composition are independent of appetite 282 
control.  283 
 Substrate Oxidation  284 
Despite a lack of studies specifically examining CLA and satiety, it is possible to discuss the 285 
potential link between the two. The glucostatic theory of appetite, developed by Mayer in the 1950s 286 
(Mayer 1953), proposed the presence of glucose receptors in the brain which respond to a 287 
fluctuation in glucose levels. Therefore, a drop in blood glucose level promotes an increase in 288 
hunger, and an increase in blood glucose (after exogenous carbohydrate ingestion) promotes the 289 
onset of satiation, due to the fact that glucose is the primary fuel for the central nervous system, and 290 
so it is tightly regulated in order to prevent hypoglycaemia (De Graaf et al. 2004; Campfield et al. 291 
1996).  CLA has been shown to increase lipolytic activity (Yeonhwa Park et al. 1997, 1999; Choi et 292 
al. 2000; Pariza, Park, and Cook 2001), which potentially may spare glucose oxidation and act as a 293 
satiety signal (Kamphuis et al. 2003; J. M. Brown and McIntosh 2003); however, this is speculative. 294 
 Leptin 295 
Leptin is a satiety-promoting hormone which is released by white adipose tissue (Perry and Wang 296 
2012). Leptin has been shown to inhibit orexigenic neuropeptide Y (NPY) and agouti-related 297 
peptide (AgRP) co-expressing neurons (Sahu 2003), meaning that the centre of the hypothalamus 298 
which promotes hunger is inhibited. Increased body fat is associated with increased leptin 299 
circulation (Myers, Cowley, and Unzberg 2008), whereas reduced sensitivity to leptin has been 300 
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shown to play a role in obesity, and can potentially be a strong driver of metabolic syndrome (Paz-301 
Filho et al. 2009; J. M. Friedman and Halaas 1998). Medina et al. (Medina 2000) observed a 302 
decrease in leptin that was significant at 7 weeks of CLA supplementation but returned to normal in 303 
the final 2 weeks. There was no effect on energy intake or body mass index (BMI) between baseline 304 
and at the end of the study, suggesting CLA decreased leptin levels independently of body fat 305 
levels. Gaullier et al. (2005) also observed decreases in circulating leptin and energy intake after 24 306 
months of supplementation with both triglyceride and free fatty acids forms of CLA. These findings 307 
suggest that, in the absence of leptin resistance, increased levels of leptin decreases energy intake 308 
(Klok, Jakobsdottir, and Drent 2007), indicating a potential mechanism for CLA-mediated satiety. 309 
Conversely, Iwata et al. (2007) reported an increase in leptin concentrations after CLA but no 310 
concurrent decrease in energy intake. However, leptin concentrations also increased in the placebo 311 
group, again with no change in energy intake indicating the changes in leptin are likely to be 312 
unrelated to CLA intake. Increased leptin concentrations was also reported after 313 
intracerebroventricular administration of CLA in rats, which decreased expression of NPY and 314 
AgRP and consequently feed intake (Cao et al. 2007). However, another study rejected the idea that 315 
CLA affects neuropeptide expression in the hypothalamus, as no CLA isomers were identified in 316 
the brain (Shelton et al. 2012). CLA did significantly decrease feed intake, but the authors suggest 317 
CLA may have altered serum hormone levels as opposed to a central mechanism.   318 
 319 
Acute intake of conjugated linoleic acid on satiety 320 
To date, there is only one study which has examined the effect of CLA on food intake (Coleman, 321 
Quinn, and Clegg 2016). In that study, participants consumed a smoothie drink containing either 322 
vegetable oil (as the control) CLA or MCT after which they consumed an ad libitum sandwich 323 
lunch, which was provided upon request. Both test fats elicited non-significant decreases at the ad 324 
libitum lunch, and intake throughout the rest of the day (and therefore overall energy intake) was 325 
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significantly lower following CLA and MCT compared to the control. CLA resulted in the longest 326 
time-to-meal request. More research is required to examine further the effectiveness of CLA as a 327 
method of reducing food intake and enhancing satiety.  328 
 329 
Effects on satiety of chronic consumption of conjugated linoleic acid  330 
Where few studies have examined CLA in the short term, there are many studies examining its 331 
effects as a long-term dietary intervention for improving body composition and reducing body 332 
weight. An excellent meta-analysis of this topic was conducted by Onakpoya and colleagues 333 
(Onakpoya et al. 2012). We have included papers which allowed for speculation as to the satiety 334 
effects of CLA.  335 
The majority of studies have not shown any significant impact of CLA on energy intake, indicating 336 
that there are satiating effects associated with CLA consumption (Cornish et al. 2009; Gaullier et al. 337 
2005; Iwata et al. 2007; E. V Lambert et al. 2007; Medina et al. 2000; Norris et al. 2009; Wanders 338 
et al. 2010). Cornish et al. (2009) investigated the combination of mixed isomer CLA, creatine and 339 
whey protein versus creatine plus placebo oil, and the placebo oil alone. Whereas there were 340 
significant increases in lean mass and strength with all three supplements combined, there was no 341 
difference in dietary intake between groups during the intervention period. The findings of Pinkoski 342 
et al. ( 2006) corroborate this, as lean mass was increased to a greater extent after 7 weeks of mixed 343 
isomer CLA supplementation alongside resistance exercise compared to a placebo. However, there 344 
was no change in self-assessed energy intake between baseline and 7 weeks between the two 345 
groups. Norris et al. (2009) reported reductions in BMI, in overweight postmenopausal women with 346 
type 2 diabetes after 36 weeks of supplementation with 6.4g/d of mixed isomer CLA. Interestingly, 347 
the decline in BMI had not yet reached a plateau, and there may have been further decreases had the 348 
study period been longer. This study also showed no difference in energy intake over the study 349 
period, which was assessed via 3-day diet diary 4 times over the intervention period. These studies 350 
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indicate that CLA may be beneficial for improving body composition and promoting weight loss; 351 
however these changes are achieved independently of satiety. Nonetheless, this is an inference 352 
based on self-reported diet diary data and satiety was not the primary measure of the 353 
aforementioned studies, and so more work is required to confirm this.  354 
In contrast, Kamphuis et al. (2003) found mixed isomer CLA dose-dependently increased feelings 355 
of fullness and decreased feelings of hunger after 13 weeks of supplementation with a low (1.8g) 356 
and high (3.6g) dose. This did not affect energy intake at breakfast, although as this was the only 357 
meal analysed it is possible that intake may have been affected during the rest of the day. Watras et 358 
al. (2007) reported that mixed isomer CLA led to decreased weight gain over a 6 month period 359 
compared to a placebo. This was especially true during the winter holiday period,  when the placebo 360 
trial subjects increased their energy intake yet there was no change in energy intake in the CLA 361 
group indicating that the CLA may have suppressed food intake. 362 
 363 
CLA does appear to be promising in the management of obesity and as a supplement to improve 364 
body composition (Blankson et al. 2000; Belury, Mahon, and Banni 2003; Gaullier et al. 2007, 365 
2005); however, this appears to be achieved without increasing satiety. Further work is required 366 
before conclusions can be drawn, especially studies focusing on satiety and not body composition. 367 
It is also noteworthy to mention that there have been some deleterious effects reported with CLA 368 
ingestion, particularly insulin resistance (Risérus, Berglund, and Vessby 2001; Medina et al. 2000; 369 
Smedman and Vessby 2001), which seems intuitive given the key role of leptin in glucose 370 
homeostasis (Denroche, Huynh, and Kieffer 2012) and the aforementioned reported decrease of 371 
leptin by CLA. An early review by Wahle and colleagues (Wahle, Heys, and Rotondo 2004) 372 
suggested that more research is warranted in order to conclude whether CLA is truly beneficial or 373 
detrimental to health.374 
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Short-chain fatty acids 375 
Short-chain fatty acids (SCFA) are carboxylic acids which are aliphatic, ranging from two carbons 376 
to four carbons in length. SCFA are made in the colon through bacterial fermentation when non-377 
digestible carbohydrates pass through the upper GI tract and reach the large intestine (Byrne et al. 378 
2015). The three main SCFA created are acetate (C2), propionate (C3) and butyrate (C4) in a ratio 379 
of approximately 60:20:20. There are also some dietary sources of SCFA such as sourdough bread, 380 
vinegar and vinegar-based products such as pickles, and finally some cheeses and other dairy 381 
products (Darzi, Frost, and Robertson 2011).  382 
 383 
Mechanisms of Satiety 384 
 Central control of appetite 385 
There are a number of potential mechanisms by which SCFA may influence satiety. These involve 386 
an increase in circulating anorexigenic hormones (Cani et al. 2006; E. S. Chambers et al. 2015; 387 
Nilsson et al. 2013) and a decrease in circulating ghrelin (Parnell and Reimer 2009). Acetate has 388 
also been shown to cross the blood-brain barrier and be taken up by the brain, specifically by the 389 
hypothalamus in both mice (Chambers et al. 2015) and humans. Appetite may be suppressed by 390 
SCFA via this mechanism, as the anorectic signal in the ARC produces increased expression of 391 
proopiomelanocortin (POMC) and reduced expression of AgRP (Frost et al. 2014). AgRP, along 392 
with NPY, is a potent stimulator of food intake, whereas POMC, along with cocaine- and 393 
amphetamine-regulated transcript (CART) provides a tonic anorexigenic signal to suppress appetite 394 
and food intake (Cone 2005; Wynne et al. 2005; Morton and Schwartz 2006; Millington 2007). 395 
SCFA may also be involved in a similar central control of feeding via intestinal gluconeogenesis 396 
(IGN). It has been shown that both butyrate and propionate stimulate IGN (Bienenstock, Kunze, 397 
and Forsythe 2015a; De Vadder et al. 2014). This is sensed by sodium-glucose cotransporters 398 
(possibly SGLT3) in the portal vein which send an afferent nervous signal to decrease food intake 399 
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(Delaere et al. 2013). Butyrate has been shown to increase directly expression of 400 
phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase catalytic subunit (G6PC) 401 
– genes involved in the regulation of IGN – 2 to 3-fold. In contrast, propionate does not directly 402 
stimulate IGN genes, but binds to FFA3, which sends signals to the parabrachial and paraventricular 403 
nuclei in the brain; driving a reflex arc to induce IGN in the gut (De Vadder et al. 2014).  404 
 405 
 Satiety Hormones and Gastric Emptying 406 
The SCFA receptors FFA2 and FFA3 have been shown to be co-expressed in L-cells which release 407 
glucagon-like peptide-1 (GLP-1) and PYY (Byrne et al. 2015). Indeed, it has been shown that 408 
propionate stimulates the release of GLP-1 and PYY via FFA2 (Psichas et al. 2014). These findings 409 
are corroborated by animal models which show that GLP-1 concentrations are decreased in FFA2 410 
knockout mice (Tolhurst et al. 2012) and likewise with PYY in FFA3 knockout mice (Samuel et al. 411 
2008). The satiating effects of PYY have already been mentioned, and GLP-1 similarly enhances 412 
satiety via a delay in gastric emptying (Flint et al. 1998; Shah and Vella 2014). GLP-1 receptors 413 
appear in areas in the central nervous system which are involved in feeding control, such as the 414 
paraventricular nucleus (PVN), the ARC and on POMC neurons (Dailey and Moran 2013; De Silva 415 
and Bloom 2012).  416 
The satiating properties of propionate have also been attributed to gastric emptying (Liljeberg and 417 
Björck 1996). Colonic contractile activity has been shown to be reduced in rats after SCFA infusion 418 
to the colon (Squires et al. 1992), but a more recent study showed no effect of colonic infusion on 419 
contractile activity in human volunteers (Jouët et al. 2013). Liljeberg and Björck (1996) found 420 
greater perceived satiety linked to slower gastric emptying after SCFA ingestion.  421 
 422 
 Other considerations 423 
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Darzi and colleagues (Darzi, Frost, and Robertson 2012) attribute the satiating effects of SCFA to 424 
the hedonic unpleasantness of propionate rather than post-absorptive mechanisms. They found no 425 
effect of bread containing a small amount of propionate, which was more acceptable and did not 426 
cause nausea, lending credence to this hypothesis. They concluded that any effects seen may be due 427 
to the palatability of orally administered SCFA, and do not support a role in appetite regulation 428 
(Darzi, Frost, and Robertson 2011). Future studies need to mask these unpleasant characteristics of 429 
the SCFA.  430 
This review aims to discuss dietary lipids and satiety. However it must be briefly mentioned that 431 
studies in mice and rats have shown that fermentable carbohydrates (such as inulin and 432 
fructooligosaccharides [FOS]) lead to production of SCFA in the large intestine (Ten Bruggencate 433 
et al. 2005; Arora et al. 2012), and this may also affect satiety. Long-term ingestion of soluble fibre 434 
may also lead to increased satiety due to increased proliferation of GLP-1 producing L-cells (Kaji et 435 
al. 2011; Kuwahara 2014). Kuwahara (2014) explains how this can only occur after long-term 436 
ingestion of FOS, as fermentation can take a number of days to occur and only then can this affect 437 
GLP-1 production. This may not manifest in changes in short-term satiety, but possibly in long-term 438 
energy homeostasis.  439 
 440 
Acute intake of short-chain fatty acids on satiety 441 
As outlined above studies examine SCFA via two methods: direct administration (such as through 442 
the use of vinegar (Kondo et al. 2009; Ostman et al. 2005)) or indirectly (through the use of fibre 443 
(Nilsson et al. 2013) and fermented dairy beverages (Ruijschop, Boelrijk, and te Giffel 2008)). 444 
Ruijschop et al. (2008) examined the use of a dairy beverage fermented with Lactobacillus 445 
acidophilus and Propionibacterium freudenreichii on satiety and food intake, and found greater 446 
feelings of satiety when compared to a placebo although there was no corresponding change in food 447 
intake. This is the only study to date, to our knowledge, which has investigated cultured propionic 448 
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acid bacteria in a dairy beverage on satiety. Despite the fact there was no effect on energy intake, it 449 
would be apposite to conduct more studies to fully elucidate its potential.  450 
A dose-response study investigating different amounts of acetate in the form of vinegar added to a 451 
bread meal found that there is a linear relationship between subjective satiety and acetate ingestion 452 
(Ostman et al. 2005). Similarly, Hlebowicz et al. investigated different breads soaked in acetic acid 453 
(white, wholemeal or wholegrain) and compared them to an un-soaked white bread control 454 
(Hlebowicz et al. 2008). While the wholegrain/acetate combination led to the greatest subjective 455 
satiety, these results must be treated with caution as there was no wholegrain control (i.e. not 456 
soaked with the acetate). Hence it is difficult to ascertain whether the wholegrain bread or the 457 
acetate influenced satiety in that study. Conversely, some studies have failed to link SCFA to 458 
satiety. Mettler et al. found no significant effect of adding either acetate, cinnamon, both, or neither 459 
to a rice pudding meal on subjective satiety (Mettler, Schwarz, and Colombani 2009). Poppit et al. 460 
(2010) also found no effect of short-chain triglycerides from soft fraction milk fat on subjective 461 
feelings of hunger or energy intake.  462 
In the review by Darzi and colleagues discussing the role of SCFA in appetite regulation (Darzi, 463 
Frost, and Robertson 2011), the authors discuss unpublished data on which they conducted pooled 464 
correlations. According to the authors, these findings suggest that acetate-containing vinegar may 465 
influence satiety through palatability effects rather than any mechanistic/physiological effects of 466 
SCFA. More recently, the same group conducted a series of experiments investigating the satiety 467 
effects of vinegar alongside a study investigating the orosensory properties of a vinegar containing 468 
beverage (Darzi et al. 2014). These studies showed that tolerability of vinegar, as opposed to 469 
palatability per se, is the cause of nausea after ingestion. This is due to the significant increase in 470 
perceived nausea after consuming the test drink but no difference when the drink was sham fed (i.e. 471 
held in the mouth and then expectorated). These findings discredit the use of vinegar as a satiety-472 
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enhancing product, as poor tolerability and nausea are possibly the main causes of reduced intake, 473 
rather than the physiological effect of activating FFA2 and FFA3. 474 
Despite systematic reviews examining both acute and chronic randomised control trials concluding 475 
that fibre only yields small satiety effects (Wanders et al. 2011) and the majority of studies failing 476 
to find significant effects (Clark and Slavin 2013), fibre may promote satiety by delaying gastric 477 
emptying and leading to a greater release of satiety hormones (Chambers, McCrickerd, and 478 
Yeomans 2015). Nilsson et al. (2013) reported that feeding healthy participants an evening meal 479 
consisting of brown beans – which contain large amounts of indigestible carbohydrates – increases 480 
circulating PYY and decreases circulating ghrelin after a standard breakfast meal. This was 481 
attributed to propionate, as concentrations were significantly increased after the brown bean meal 482 
compared to the control. However, the results of this study could also be due to other characteristics 483 
of fibre and not SCFA exclusively. Tarini and Wolever (2010) found concentrations of plasma 484 
GLP-1 were increased and serum ghrelin were decreased after 24g of inulin was added to a test 485 
drink; effects attributed to increased colonic SCFA production. Considering that the daily reference 486 
value for fibre is 30g·day, this is a large bolus of fibre to consume in a single sitting; but it does 487 
demonstrate the potential for fermentable fibre to mediate satiety, possibly through increased SCFA 488 
levels in the gut. 489 
Effects on satiety of chronic consumption of short-chain fatty acids  490 
Current knowledge on SCFA is limited as the majority of studies conducted to date are in animal 491 
models, with more studies in human participants required to elucidate the effects and mechanisms 492 
of SCFA on energy expenditure, intake, and balance. Kondo et al. (2009) conducted the first study 493 
to investigate the effect of SCFA (in the form of acetic acid present in vinegar) on body 494 
composition. This double-blind parallel study administered beverages with either no vinegar 495 
(control) or a low or high dose (15 and 30 ml, respectively) of cider vinegar for 12 weeks. They 496 
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found that body composition was improved in a dose-dependent manner, showing that acetic acid, 497 
in the form of vinegar, can beneficially alter body composition, fat mass, and body weight. 498 
However, there were no differences between any of the groups during the supplementation period 499 
for energy intake, macronutrient composition of foods eaten or physical activity. From this, we may 500 
infer that the beneficial effects of orally ingested acetate, the most abundant of the SCFA, are not 501 
linked to satiety. Conversely, in a study by Cani et al. (2006) two 8g portions of oligofructose were 502 
taken at breakfast and dinner for two weeks. Subjective satiety after an ad libitum breakfast was 503 
significantly higher than baseline after the supplementation and intake was lower at the meal. Intake 504 
was also lower at the ad libitum lunch provided, but not at dinner, corresponding to a significant 505 
decrease in energy intake throughout the whole day of approximately 5% after oligofructose intake. 506 
Despite discussing the fermentation of fibres at length and commenting on SCFA production, this 507 
paper, unfortunately, did not measure SCFA production, which would have allowed for a link 508 
between satiety and SCFA. SCFA concentrations, however, were reportedly increased after 6 weeks 509 
of oligofructose supplementation in another study, which corresponded to decreased energy intake 510 
and reported hunger, as well as increased PYY (Daud et al. 2014). Similarly, Chambers et al. 511 
measured the release of GLP-1 and PYY from L cells in vitro and found that SCFA led to 512 
significant increases in hormone release above basal levels (Chambers et al. 2015). That group 513 
produced a novel ester which bound propionate to inulin by an ester bond. This allowed delivery of 514 
propionate to the gut as inulin which was fermented by colonic fermentation, thereby releasing the 515 
propionate. In a 24-week follow-up supplementation study in 49 volunteers, 10g of propionate per 516 
day led to significant reductions in energy intake of 14% compared to the control group. This 517 
decrease was attributed to the increased stimulation of GLP-1 and PYY that the authors found in the 518 
in vitro part of the study. Similarly, Freeland et al. (2010) reported increased plasma butyrate and 519 
increased GLP-1 release after chronic intake of fibre. This may outline the mechanisms behind 520 
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SCFA and satiety, although these results were only observed after 9 months of intake (20g of 521 
fibre·day over baseline intake).  522 
Clearly, the literature surrounding SCFA is far from unequivocal, although it is possible that the 523 
specific SCFA may exert different effects on satiation and body composition. This is an avenue for 524 
future work.  525 
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Diacylglycerol 526 
Diacylglycerol (DAG) is a glyceride which consists of two fatty acids on a glycerol backbone and 527 
naturally occurs in small amounts in cooking oils; from 0.8% in rapeseed oil to 5.5% in olive oil 528 
and 9.5% in cottonseed oil (Rudkowska et al. 2005; Flickinger and Matsuo 2003; D’Alonzo, 529 
Kozarek, and Wade 1982). In 1999, the Kao Corporation in Japan introduced DAG oil which 530 
contained over 80% DAG and sold over 70 million bottles between then and 2003 (Flickinger and 531 
Matsuo 2003).  532 
 533 
Mechanisms of Satiety 534 
 Substrate Oxidation 535 
Chronic studies examining the effects of DAG on weight loss have attributed the decrease in 536 
adipose tissue to greater levels of β-oxidation (Maki et al. 2002; Nagao et al. 2000), although to the 537 
authors’ knowledge only one study has directly measured this (Kamphuis, Mela, and Westerterp-538 
Plantenga 2003). Scharrer and Langhans (1986) first established that inhibited fatty acid oxidation 539 
stimulates feeding, and since then hepatic fatty acid oxidation has been linked with hunger (Kahler, 540 
Zimmermann, and Langhans 1999). Therefore the decrease in appetite shown in the study by 541 
Kamphuis et al. (2003) could be attributed to the lipoprivic control of eating.  542 
 543 
 Gastric Motility 544 
The transport and absorption of DAG are similar to medium-chain triglycerides, despite the fact it is 545 
mainly comprised of long-chain fatty acids. Long-chain fatty acids (≥12 carbon atoms) slow gastric 546 
emptying – the rate of food leaving the stomach and entering the duodenum (Clegg and Shafat 547 
2009) – to a greater extent than shorter chain fatty acids (Hunt and Knox 1968). It has been shown 548 
that gastric emptying is correlated with satiety, and therefore the longer food remains in the stomach 549 
the greater is the satiating effect (Bergmann et al. 1992; Geliebter 1988). Therefore it is possible 550 
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that DAG may influence satiety through delayed gastric emptying, although this is only speculation 551 
as there are currently no studies which have investigated this.  552 
 553 
 Satiety Hormones 554 
Stoeckel et al. (2008) compared the effect of a high-fat beverage consisting mainly of DAG to a 555 
very low-calorie beverage on PYY release. Participants were divided into either high PYY release 556 
or low PYY release groups. In the high PYY group, the response was significantly higher after the 557 
DAG drink compared to the low-calorie drink, which also corresponded to decreased ratings of 558 
hunger. No other study to the authors’ knowledge has reported PYY ‘non-responders’ and it is not 559 
currently known why this study found this. It is tempting to speculate an effect of DAG on PYY 560 
release; however without a control oil to compare it to it is impossible to say whether this response 561 
is similar to other long-chain oils. 562 
 563 
Acute intake of diacylglycerol on satiety 564 
As aforementioned, Kamphuis, Mela and Westerterp-Plantenga (2003) examined the effect of 565 
energy-balance diets for 4.5 days on substrate oxidation, energy expenditure, and subjective 566 
appetite when 40% of the fat provided was either DAG or TAG oil. On the fourth day, DAG oil 567 
intake was 33.0 ± 2.3 g which provided 26.4 ± 1.9 g of DAG, and on the fifth day, DAG oil intake 568 
was 22.2 ± 1.4 g which provided 17.8 ± 1.1 g of DAG. DAG oil led to decreased subjective hunger 569 
and increased subjective satiety, which was attributed to higher rates of β-oxidation. Participants 570 
were fed a prescribed amount in order to achieve energy balance, and so whether these subjective 571 
feelings would lead to changes in ad libitum intake is unknown. Given that the inhibition of fatty 572 
acid oxidation stimulates hunger (Langhans et al. 2011; Leonhardt and Langhans 2004), it is 573 
possible that this increase in β-oxidation will have the opposing effect and prevent hunger, although 574 
this requires further study. To the authors’ knowledge, this is the only study to date which has 575 
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investigated the role of DAG on appetite. Taking into account the potential for cumulative 576 
mechanisms which could lead to enhanced satiety, this is an exciting avenue for further research.  577 
 578 
Effects on satiety of chronic consumption of diacylglycerol  579 
It has been repeatedly shown that chronic intake of DAG can lead to decreased body weight and 580 
reduced accumulation of adipose tissue (Kawashima et al. 2008; Li et al. 2008; Yasunaga et al. 581 
2004; Maki et al. 2002; Yamamoto et al. 2001; Taguchi et al. 2001). There are clearly some long-582 
term benefits associated with the intake of DAG, although this is outside the scope of the current 583 
review; however, readers are directed to the meta-analysis of Xu et al. (2008). To the authors’ 584 
knowledge, no study to date has investigated chronic DAG intake on satiety specifically. Self-585 
reported diet diary data suggests that DAG has no long-term effect on satiety (Yamamoto et al. 586 
2001) or can decrease energy intake but no more than a triacylglycerol control oil (Kawashima et al. 587 
2008). Li et al. (2008) found that carbohydrate intake was decreased after 120 days of DAG 588 
supplementation, but the decrease in total energy intake only approached significance (P = 0.08). It 589 
is noteworthy to mention that the study by Kawashima and colleagues (2008) administered DAG oil 590 
in an ad libitum protocol where participants merely swapped their normal cooking oil with DAG 591 
oil. This is of particular importance as most studies administer lipids by adding extra lipid to food, 592 
such as yoghurt (Kamphuis, Mela, and Westerterp-Plantenga 2003) or a beverage (Stoeckel et al. 593 
2008), and so this ad libitum protocol has been shown to yield significantly positive effects without 594 
administering set doses. This study also reported no differences in fasting ketone bodies after the 595 
treatment period, which suggests the increase in hepatic fatty acid oxidation is transient. It would be 596 
pertinent to investigate if there is increased postprandial β-oxidation after chronic DAG 597 
supplementation to elucidate whether there is an added benefit to short-term intake. However, the 598 
current evidence suggests that DAG supplementation does not increase satiety.599 
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Omega-3 Polyunsaturated Fatty Acids 600 
Omega-3 (n-3) polyunsaturated fatty acids (PUFA) are essential fatty acids as they cannot be 601 
synthesized de novo (Lorente-Cebrián et al. 2013). The main n-3 PUFA are eicosapentaenoic acid 602 
(EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) which are found in large quantities in 603 
certain fish, such as mackerel, salmon, and sardines; therefore these are considered to be ‘fish oils’ 604 
(Ackman 2008). Whereas n-6 PUFA possesses inflammatory properties by leading to the secretion 605 
of the proinflammatory cytokine interleukin-1 and the leukotriene LTB4, n-3 PUFA are anti-606 
inflammatory and may help protect against inflammatory and autoimmune diseases (Simopoulos 607 
2002). Research has shown positive effects of fish oil on cardiovascular diseases (Chowdhury et al. 608 
2012; Ebrahimi et al. 2009), dyslipidaemia (Paniagua et al. 2011; Jiménez-Gómez et al. 2010) and 609 
body composition (Bender et al. 2014), however few studies to date have investigated the effect of 610 
n-3 PUFA on satiety and food intake. 611 
 612 
Mechanisms of Satiety 613 
 Central control of appetite 614 
The endocannabinoid system is a complex system with various physiological roles, one of which is 615 
the regulation of food intake (Pagotto et al. 2006). Lipids have diverse roles in the control of 616 
appetite through this system, such as the orexigenic anandamide (N-arachidonoylethanolamine, 617 
AEA) and the opposing anorexigenic oleoylethanolamide (OEA) (Lambert and Muccioli 2007; 618 
Petersen et al. 2006). Levels of gut OEA are low during prolonged fasting and rise postprandially, 619 
and OEA has been shown to suppress food intake in rats through peroxisome proliferator-activated 620 
receptor α (PPARα) (de Fonseca et al. 2001; Fu J. et al. 2003). In contrast, anandamide has been 621 
shown to increase appetite to the point of inducing over-consumption (Williams and Kirkham 622 
1999). Wood et al. (2010) noted that DHA-enhanced mouse-chow led to decreased plasma 623 
concentrations of both OEA and AEA, which may suggest a homeostatic mechanism in order to 624 
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maintain energy balance. However, given that OEA can exerts its anorexigenic effects when 625 
accumulating locally in the intestine without affecting plasma levels (Borrelli and Izzo 2009), this 626 
requires further research for confirmation.  627 
 628 
As briefly mentioned previously, the hypothalamus is the main centre of the brain for regulating 629 
energy intake. In recent years, there has been emerging evidence that other areas of the brain are 630 
involved with energy intake, such as mesolimbic dopamine system (Volkow, Wang, and Baler 631 
2011). The controversial idea of categorising appetite as an addiction and obesity as a 632 
neurobehavioral disorder has been proposed in recent years (Dagher 2009), and in this context, 633 
obesity may be a result of the excess energy intake from the consumption of energy dense foods due 634 
to their potent reward. Chalon (2006) found that the mesolimbic dopaminergic pathway was 635 
overactive in rats with n-3 PUFA deficiency, and this could possibly manifest in changes in eating 636 
behaviour due to its role in reward-seeking behaviours, such as the consumption of palatable foods. 637 
Indeed, Cordeira et al. (2010) found that depleted brain-derived neurotrophic factor (BDNF) led to 638 
increased intake of chow in mice due to modulation of the mesolimbic dopamine system. Further 639 
research is required to investigate the link between n-3 PUFA and the mesolimbic system, but if 640 
supplementation can suppress reward-seeking behaviour, it could be a useful tool for decreasing 641 
energy intake.  642 
 643 
 Increasing appetite  644 
It is important to remember that not all individuals need to reduce their energy intake. Patients with 645 
cancer can suffer from cancer anorexia-cachexia, the muscle wastage that occurs as a result of the 646 
disease (Dodson et al. 2011). One of the complications of this condition is poor appetite, possibly 647 
due to cytokine-inhibition of neuropeptide Y (Donohoe, Ryan, and Reynolds 2011). 648 
Supplementation with n-3 PUFA can reduce the production of interleukin-1 and interleukin-6 649 
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cytokines (Barber, Ross, and Fearon 1998). Therefore, supplementation with EPA may help combat 650 
the loss of appetite associated with this condition. This suggests that there may be a role for n-3 651 
PUFA in overall energy intake regulation, managing both over- and under-consumption. 652 
 653 
Acute intake of omega-3 PUFA on satiety 654 
To the authors’ knowledge, there are no studies to date which have investigated the acute effect of 655 
n-3 PUFA intake on satiety. n-3 PUFA appears to mediate its effects by increasing the phospholipid 656 
content of the cell membrane of EPA and DHA (Calder 2010), which occurs in a dose-dependent 657 
manner after supplementation (Rees et al. 2006). Therefore, there may be no benefit to satiety when 658 
n-3 PUFA are taken acutely. Some studies have found that n-3 PUFA ingestion can lead to mild 659 
side-effects, such as nausea (Bruera et al. 2003), and have an unpleasant taste (Damsbo-Svendsen, 660 
Rønsholdt, and Lauritzen 2013). These are factors which must be taken into consideration when 661 
studies assessing acute intake of n-3 PUFA on satiety are designed, as they may confound the 662 
results. 663 
 664 
Effects on satiety of chronic consumption of omega-3 PUFA  665 
Studies have measured the effect of n-3 PUFA in various chronic diseases, whereas the role of n-3 666 
PUFA in satiety has received little attention. The current evidence is equivocal. Parra et al. (2008) 667 
examined the use of seafood diets and fish oil capsules on appetite in overweight and obese 668 
participants who were already undergoing caloric restriction, and found that participants in the high 669 
n-3 PUFA groups reported increased fullness and decreased hunger and desire to eat after a test 670 
meal, assessed by visual analogue scale after the evening meal, which was consumed in habitual 671 
conditions. However, it is difficult to conclude whether these effects are chronic effects from the 672 
supplementation and diet manipulation or acute effects from the test meals, as the test dinners 673 
differed between groups (cod in the low n-3 group, salmon in the high n-3 group). This does 674 
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indicate that the long-term intake is associated with appetite suppression, but more research is 675 
needed to confirm this. Furthermore, this study did not measure pre-meal appetite sensations and 676 
therefore the results must be interpreted with caution, as differences from baseline may have 677 
affected the results. Damsbo-Svendsen et al. (2013) found that fish oil tablets were not as effective 678 
as soybean tablets for increasing satiety, as they reported that postprandial fullness was increased 679 
and desire to eat decreased after soybean supplementation for 3 weeks. However, the washout 680 
period in this study was one week long, and this may not be enough to completely remove any 681 
effects from the previous supplementation (Brown, Pang, and Roberts 1991; Hansen et al. 1998).  682 
Interestingly, Bruera et al. (2003) found that appetite decreased in both an intervention group and a 683 
control group. The aim of that study was to investigate whether n-3 PUFA can aid patients with 684 
cachexia, which can manifest in symptoms such as weight loss and a reduction in appetite. 685 
Unexpectedly, results from this study showed that appetite decreased in patients with cancer 686 
cachexia, although it has been previously shown that supplementation with EPA can improve 687 
appetite in these patients (Barber et al. 1999). Jatoi et al. (2004) examined the use of supplementing 688 
1.09 g of EPA and 0.46 g of DHA versus the appetite stimulating progesterone megestrol acetate, 689 
and found no differences between the two (or a combination) in terms of appetite, as appetite 690 
ratings increased in all three arms. Where this showed no benefit of EPA compared to megestrol, it 691 
does show the ability of EPA to increase appetite in cachexia. Similar results have been found in 692 
Yehuda et al. (2005) who reported that a mixture of n-3 and n-6 fatty acids led to increased 693 
subjective appetite in those who suffered test anxiety compared to a placebo mineral oil. It was 694 
again further corroborated by Zaid et al. (2012), who found that there was an increase in subjective 695 
appetite ratings in children with leukaemia after 8 weeks of supplementation with 360 mg EPA and 696 
240 mg DHA daily. These results also indicate that n-3 may be useful in appetite control, but for 697 
those who need to increase appetite and not for those undertaking a weight loss intervetion.  698 
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Clearly, more research is needed in healthy volunteers and in a cohort attempting to lose weight. 699 
Some of these studies have shown that n-3 PUFA supplementation can increase appetite in 700 
inflammatory diseases (such as cancer cachexia), but, counterintuitively, they have also been shown 701 
to be beneficial in weight loss as well. More research is needed to strengthen our understanding of 702 
the role of n-3 PUFA in the modulation of appetite.703 
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Small Particle Lipids 704 
Research into lipid droplets is a relatively new field, as it was believed until the early 1990s that 705 
they were inert deposits (Suzuki et al. 2011). Lipids droplets consist of a core of lipids surrounded 706 
by a phospholipid monolayer (Tauchi-Sato et al. 2002; Fujimoto and Parton 2011) and range in size 707 
from 0.3 μm to 20 μm in various milks and infant formulas (Favé, Coste, and Armand 2004). Small 708 
particle lipids (SPL) are created via fractionation.  709 
 710 
Mechanisms of Satiety 711 
 Digestion 712 
Smaller lipid droplets lead to increased emulsion surface area, meaning that fat hydrolysis will 713 
increase, as lipase is active on the surface (Maljaars et al. 2012). Armand (Armand 2007) states that 714 
as lipase is abundant, therefore a larger lipid/surface inter-surface area allows for extra binding. 715 
Also, human pancreatic lipase is inhibited by large amounts of free fatty acids which accumulate at 716 
the surface of lipid droplets; a greater surface area delays this inhibition, thereby increasing the 717 
amount of hydrolysis (Armand et al. 1999; Patrick Borel et al. 1994). Increased rates of hydrolysis 718 
may increase satiety by increasing fatty acid sensing in the small intestine (Maljaars et al. 2012). 719 
Borel et al. (1994) conducted the first in vivo (in rats) study examining lipid droplet size and 720 
digestion, and found that finer emulsions led to greater hydrolysis than coarser emulsions. These 721 
findings were confirmed in healthy humans a few years later when emulsions were administered 722 
intragastrically (Armand et al. 1999). Furthermore, CCK was more potently released with 723 
emulsified LCT – with reduced droplet size – than non-emulsified LCT (Ledeboer et al. 1999).  724 
 Gastric Motility 725 
The concept of the ‘ileal brake’ was first established in the mid-1980s and was shown to both 726 
reduce jejunal motility (Spiller et al. 1984) and delay gastric emptying (Read et al. 1984). The ileal 727 
brake has been shown to delay gastric emptying to a greater extent than the duodenal brake (Welch, 728 
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Saunders, and Read 1985; Maljaars et al. 2012). This was confirmed in later studies by the 729 
University Hospital Maastricht research group who showed that smaller lipid droplets led to 730 
increased peptide secretion and satiety scores over larger droplets, but only when infused into the 731 
ileum and not the duodenum (Maljaars et al. 2012). It must be noted that droplet size does also 732 
appear to have an effect when administered to the duodenum, as Seimon et al. (2009) found that 733 
infusion of lipids with a droplet size of 0.26 μm led to greater stimulation of CCK, PYY and hunger 734 
suppression, leading to decreased energy intake. However, it was also found in another study that 735 
this was only apparent when fat is infused as compared to oral consumption of the same load 736 
(Maljaars et al. 2011). However, intragastric infusions are not a feasible method of decreasing 737 
energy intake.  738 
 739 
Acute intake of small particle lipids on satiety 740 
FabulessTM (previously OlibraTM) is an emulsion comprised of palm oil and oat oil, produced by 741 
DSM (Delft, the Netherlands). GI transit time has been shown to be delayed when FabulessTM was 742 
delivered intra-gastrically (Knutson et al. 2010). Early studies conducted at the University of Ulster 743 
showed that this product decreased energy intake by an impressive 22-27% when compared to a 744 
control fat in lean, overweight and obese subjects (Burns et al. 2002, 2001, 2000). These results 745 
have, unfortunately, not been replicated (Smit et al. 2011; Smit et al. 2012; Chan et al. 2012), even 746 
by the same research group (Logan et al. 2006). Smit and colleagues investigated the possible role 747 
in the processing of the emulsion, and even with minimal processing (i.e. no shear and a maximum 748 
temperature of 42°C), there were effects on subjective appetite or energy intake (H. J. Smit et al. 749 
2012). This may explain why the early studies from Burns’ group found positive effects, whereas 750 
later studies did not; as processing may have rendered the active ingredient in the test drinks 751 
inactive. In reality, this study concludes there is no efficacy of FabulessTM in improving satiety.  752 
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Fractionated oat oil (LOO) has a smaller particle size than milk globules (100 nm vs 1000 nm) and 753 
may remain partially undigested when entering the ileum. It has been shown to result in increased 754 
circulation of PYY, GLP-1, and CCK, but no changes in energy intake (Ohlsson et al. 2014). The 755 
authors claim that the concentration of polar lipid in the oil investigated is considerably higher than 756 
those in FabulessTM, and the resulting liposomes are stable enough to pass through the stomach 757 
without structural changes. This may explain the larger effect seen in postprandial concentrations of 758 
CCK, PYY, and GLP-1 with LOO compared to FabulessTM, but further study is required to confirm 759 
this.  760 
Peters et al. (2014) reported no effect of droplet size when administered in a meal-replacement 761 
drink, and they discuss the potential for the background effect of the drink (which contained 10g of 762 
protein in the 606 kJ drink) which may have decreased sensitivity to the lipids added. This is in 763 
spite of the fact that lipolysis was significantly higher in the smaller droplet (0.1 μm) compared to 764 
the larger droplet (3 μm). Marciani et al. (2009) showed that acid-unstable emulsions were broken 765 
down in the stomach before entering the small intestine, whereas acid stable emulsions were not and 766 
led to slower gastric emptying and greater satiety scores. A more recent study also found no 767 
increase in subjective satiety or a decrease of energy intake when comparing FabulessTM soft lipid 768 
emulsions or hard emulsions (dairy and palm oil, respectively) which were matched for particle size 769 
(Chan et al. 2017). The aforementioned findings regarding site delivery and acid stability may 770 
explain the lack of significant difference between the droplet sizes in the study by Peters and 771 
colleagues. Hussein et al. (2015) added locust bean gum to lipids of 6 μm or 0.4 μm and found that 772 
these were more stable than a control coarse lipid of 6 μm with no locust bean gum. This stability 773 
allowed for delivery of the lipids to the duodenum, and resulted in slower gastric emptying and 774 
decreased food intake, without altering subjective sensations of appetite. This shows that the 775 
development of novel foods containing small lipid droplets which remain unchanged in the stomach 776 
until breakdown in the duodenum could be a promising avenue to increase satiety. 777 
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 778 
Effects on satiety of chronic consumption of small particle lipids  779 
To the authors’ knowledge, only three studies to date have investigated SPL chronically, and these 780 
investigated FabulessTM. Logan et al. (2006) found no significant suppressive effects of the novel 781 
lipid emulsion on either satiety or food intake. There are some methodological limitations which 782 
may have affected the results, such as the ad libitum trials being conducted in social environments 783 
instead of a secluded booth. However, despite errors in design, this study does not support the 784 
previous findings of FabulessTM as a long term mediator of satiety. Diepvens et al. (2007) found that 785 
hunger was significantly decreased, and weight re-gain was significant in the placebo group but not 786 
in the emulsion group, indicating FabulessTM may be useful in weight maintenance. However, Heer 787 
(2012) discussed that the 1.2 kg difference in body mass between groups may not be clinically 788 
significant or even attributed to the emulsion, as this can be achieved with a negative energy 789 
balance of 100 kcal·day over the 18 week period. A more recent study investigated the concurrent 790 
application of a low-calorie diet (1500 kcal·day), an exercise program, and supplementation of 4.2 g 791 
of Olibra or 3.9 g milk fat for a 12 week period (Rebello et al. 2012). They concluded no significant 792 
effect of supplementation with the emulsion on energy intake, subjective feelings of fullness or 793 
body weight/composition. Thus, there appears to be little evidence that FabulessTM can be useful in 794 
promoting satiety and decreasing energy intake.  795 
More studies are required, examining different small lipid droplet emulsions and satiety, to confirm 796 
whether there is a long-term effect. It would be beneficial to develop a novel lipid or food product – 797 
such as capsules – which could release smaller lipid droplets directly into the ileum. Once this has 798 
been developed and shown to decrease satiety when administered acutely, then chronic strategies to 799 
enhance satiety can be examined.800 
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Discussion and future directions 801 
There is some evidence to suggest that the lipids included in this review do provide satiating effects; 802 
however, the side effects of taking these, particularly in high doses, must be taken into 803 
consideration. The evidence presented here suggests that the lipids with the most potential to 804 
enhance satiety are MCTs. SCFA can also promote satiety, but oral administration is more likely 805 
linked to poor tolerability rather than a satiety effect. MCT have been shown to enhance satiety 806 
when administered in beverage form (Rolls et al. 1988), when added to pasta (Van Wymelbeke et 807 
al. 1998), and non-significant trends have been seen when incorporated into a fried breakfast 808 
(Clegg, Golsorkhi, and Henry 2013). As aforementioned, MCT exert their appetite-suppressing 809 
effects through an increase in ketone body production and not by an increase in appetite-810 
suppressing hormones. Therefore it is possible that combining MCT alongside other nutrients that 811 
are potent stimulators of hormone release, such as protein (van der Klaauw et al. 2013) or indeed 812 
other fats (Huda, Wilding, and Pinkney 2006; McLaughlin et al. 1999), would lead to an even 813 
greater satiety response, although this is speculative. 814 
Only one study to date has investigated CLA, and CLA led to reduced energy intake compared to a 815 
control, but with no significant difference to MCT (Coleman, Quinn, and Clegg 2016). There was 816 
no difference in self-reported hunger, fullness, desire to eat or prospective food consumption 817 
between any of the three oils. Further studies should aim to analyse this further, in different modes 818 
of delivery (i.e. liquid vs solid food).  819 
SCFA do appear promising in the promotion of satiety, although this is difficult to quantify due to 820 
the background effect of fibre utilised in many studies (Nilsson et al. 2013; Johansson et al. 2013; 821 
Hlebowicz et al. 2008). Earlier studies investigating oral administration of SCFA initially seemed 822 
promising, with reported increases in satiety (Ostman et al. 2005; Hlebowicz et al. 2008; Kondo et 823 
al. 2009). A recent paper by Darzi and colleagues concluded that the apparent satiety effect is 824 
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actually poor tolerability (Darzi et al. 2014). Whilst this indicates that oral administration of these 825 
SCFA (acetate and propionate) is not recommended, no study to date has investigated oral 826 
administration of butyrate. It is likely that the same result will be seen, and so studies investigating 827 
this should consider nausea as a possible explanation for any apparent satiety effect.  828 
DAG may influence satiety through a variety of mechanisms. The major limitation of DAG is its 829 
availability. The product used in some of the studies mentioned in this review (Maki et al. 2002; 830 
Yamamoto et al. 2001; Kamphuis, Mela, and Westerterp-Plantenga 2003) has since been withdrawn 831 
from production, due to the presence of the carcinogenic glycidol fatty acid ester. DAG oil has been 832 
verified as safe, with no adverse effects reported during 12 weeks of supplementation with a high 833 
dosage of 0.5 g·kg·d (Yasunaga et al. 2004), although the DAG in this study was created by the 834 
research group and not purchased commercially. Until a safe version of DAG is available which can 835 
be purchased commercially, this does not appear to be a feasible avenue for the promotion of 836 
satiety. 837 
The evidence in support of fish oil and SPL is equivocal at best, with a majority of the research 838 
indicating no benefit of SPL (Y. K. Chan et al. 2017; Peters et al. 2014), despite earlier studies 839 
suggesting otherwise (Burns et al. 2001, 2000, 2002). In one study, fractionated oat oil was shown 840 
to increase satiety and the circulating concentration of satiety hormones (Ohlsson et al. 2014), and 841 
so more data is required to support these initial positive findings. n-3 PUFA can possibly be utilised 842 
in increasing appetite in scenarios where this is necessary, such as in cancer patients (Jatoi et al. 843 
2004; Zaid et al. 2012). There is a lack of studies investigating n-3 PUFA and satiety, and some of 844 
the current evidence did not measure satiety or appetite specifically.  845 
A recurring limitation of the use of functional lipids in the enhancement of satiety is the adverse 846 
side effects commonly reported (Table 1). Both CLA and fish oil supplementation have been 847 
reported to result in adverse side-effects in small doses of 6.8 g·d with CLA (Blankson et al. 2000) 848 
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and 5 ml·d with n-3 PUFA (Damsbo-Svendsen, Rønsholdt, and Lauritzen 2013). Intakes of 85 g 849 
have been reported with MCT (Jeukendrup et al. 1998). Where this high amount did result in GI 850 
distress, it does show the potential for larger increases in satiety compared to some other lipids.  851 
In conclusion, future work should examine the combination of these lipids with other 852 
macronutrients (including fat) and other methods of promoting a negative energy balance in order to 853 
assess the cumulative effects. As there is currently no study directly comparing the effects of these 854 
lipids, it would be pertinent for this to be investigated. Finally, only one of the studies discussed in 855 
this review has employed a design by which the participants swapped their daily oil for the test oil 856 
(Kawashima et al. 2008). Considering that adding lipids to foods is counter-intuitive to an 857 
individual attempting to decrease energy intake, this protocol should be examined in more studies 858 
for ecological validity.  859 
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Table 1. Studies on the effect of medium chain triglycerides (MCT) on satiety 
Study Study Design Fat used Major Results 
Barbera et al. (2000) Infusion study 
0.9% Saline, 20% LCT or 22% MCT 
emulsions 
↑ gastric volume and satiation after LCT  
 ↑ gastric volume after MCT but not 
enough to induce the same satiation 
↑ CCK, GIP, neurotensin and PP after LCT 
Feltrin et al. (2004) Infusion study 
Lauric acid (C12), Decanoic acid (C10), 
and control infused at a rate of 0.375 
kcal min-1 
Both C12 and C10 elicited CCK release, ↑ 
in C12 
↓ subjective sensations of hunger and EI 
after C12 
Krotkiewski et al. 
(2001) 
4 week very low-calorie diet 
in peri-menopausal women 
9 g MCT, 8.8 g LCT or low-fat control (3 
g fat) 
MCT ↓ hunger and ↑ satiety  
  ↑ ketones in MCT 
MCT ↑ BW loss after 2 weeks, but no 
difference by week 4 
Maas et al. (1998) Infusion study 
LCT (corn oil) or MCT (octanoic and 
decanoic acid) infused at a caloric load 
of 22.7 kJ min-1 and 11.6 kJ min-1 
respectively 
↑ PYY secretion after LCT 
PYY was released after MCT, to a lesser 
extent 
McLaughlin et al. 
(1999) 
Infusion study 
Various fatty acids of different chain 
lengths from butyric acid (C4) to 
octadecanoic acid (C18) 
Fatty acids with chain length ≤11C: ↔ CCK 
secretion 
Fatty acids with chain length ≥12C: ↑ CCK 
secretion 
Poppit et al. (2010) 
High-fat breakfast in healthy 
men 
SCT (milk fat), MCT (coconut oil) or LCT 
(tallow). Ad libitum meal 210 min after 
breakfast 
↔ ad libitum EI 
↔ subjective sensations between trials  
Rizzo et al. (2016) 
Preload study in 36 healthy 
women 
Ice cream containing different ratios of 
coconut oil (CO) and sunflower oil (SO) 
↓ fat intake after High CO 
Inverse trend of CO and EI at dinner, but 
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High CO: 75%CO:25%SO 
Equal: 50:50 
High SO: 75%SO:25%CO 
non-significant 
↔ EI between trials 
Rolls et al. (1988) 
Preload study in 24 women, 
12 dieters, and 12 non-
dieters 
30% fat liquid preload of which all 30% 
LCT or 24% MCT and 6% LCT 
3 doses of each providing 100, 200 or 
300kcal 
↓ ad libitum EI after MCT 
Larger doses led to ↓ EI 
↔ subjective sensations  
No consistent pattern emerged in dieters  
St-Onge et al. (2014) 
2 studies: one breakfast 
study and one preload study.  
Both studies: breakfast containing 20g of 
either MCT or LCT (corn oil) 
Preload study: 3h after breakfast 
participants consumed a preload yoghurt 
containing an extra 10g of either oil. 
↓ intake at ad lib lunch after MCT 
↑ PYY and leptin after MCT 
↔ total ghrelin and GLP-1 
↑ suppression after preload as opposed to 
the breakfast 
Van Wymelbeke et 
al. (1998) 
High carbohydrate breakfast 
in 12 healthy volunteers  
4 high CHO breakfast with either 70 kJ fat 
substitute, or 1460 kJ from different fats: 
saturated LCT (from 42 g lard), 
monounsaturated LCT (from 40 g olive 
oil) or MCT (from 43 g of Ceres MCT 
oil). 
↓hunger after MCT 
↔ in time to request lunch other than ↓ in 
fat substitute  
↔ in time to request dinner 
Van Wymelbeke, 
Louis-Sylvester and 
Fantino (2001) 
Preload lunch in 10 men 
4 lunches: 
2310 kJ meal containing 40 kJ fat 
substitute (Sub), 32 g LCT, 35 g MCT or 
53 g CHO and 8 g LCT (CHO) 
↑ delay in meal request in CHO 
↑ delay in MCT over LCT and Sub, but not 
as long as CHO 
↓ EI in MCT 
MCT: Medium-chain triglycerides; LCT: Long-chain triglycerides; EI: Energy Intake; CCK: Cholecystokinin; GIP: Gastric Inhibitory Peptide; 
PP: Pancreatic Polypeptide; BW: Body Weight; CHO: Carbohydrate. ↑ shows increased or greater ↓ shows decreased or lesser ↔ shows no 
change or difference. 
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Table 2. Studies on the effect of conjugated linoleic acids on satiety 
Study Study Design Fat used Major Results 
Blankson et al. 
(2000) 
12 weeks supplementation 
study 
CLA capsules: 75% CLA, equal parts 
c9,t11 and t10,c12 isomers 
Placebo capsules: olive oil 
Varying dosages: Placebo: 9g olive oil. 
CLA doses of 1.7g, 3.4g, 5.1g or 6.8g 
↓ Appetite after 12 week period in 3.4g and 
7.8g CLA groups 
↑ Lean mass after all CLA doses. 
Coleman, Quinn and 
Clegg (2016) 
Preload breakfast in 19 men 
22g vegetable oil (control) 
5 g CLA and 16g vegetable oil (CLA) 
25 g MCT oil (MCT) 
↓ (non-sig) EI at ad libitum lunch in both 
CLA and MCT 
↓ Overall EI in MCT 
↑ Time to meal request in CLA 
Cornish et al. (2009) 
5-week strength training, 69 
participants 
3 groups: 
6 g·day CLA (36.1% c9,t11 and 36.3% 
t10,c12 isomers), 36 g·day whey and 9 
g·d creatine (CPP) 
36 g·day whey, 9 g·d creatine and placebo 
oil (CP)  
Placebo oil (P) 
↔ EI in all groups from baseline to 12 
weeks and between groups from self-
reported diet diary data 
Gaullier et al. (2005) 
2 year CLA supplementation 
study 
4.5 g·d olive oil (Placebo) 
4.5 g·d Triglyceride CLA (CLA-TG) 
providing 3.4 g active isomers 
4.5 g·d Free fatty acid CLA (CLA-FA) 
providing 3.6 g active isomers 
↓ EI by 1289kJ·day in CLA-TG 
↓ EI by 870kJ·day in CLA-FFA  
↓ Leptin both CLA-TG and CLA-FFA 
Iwata et al. (2007) 
12 weeks supplementation in 
60 healthy volunteers 
5.4 g CLA-triacylglycerol (3.4 g as CLA 
isomers) 
10.8 g CLA- triacylglycerol (6.8 g as CLA 
↔ In energy intake after treatment: no 
effect of CLA on satiety 
↑ Leptin in all groups (including placebo) 
62 
 
isomers)  
Placebo (10.8 g safflower oil)  
CLA comprised ~50:50 c9,t11 and t10,c12 
isomers 
Kamphuis et al. 
(2003). 
3 weeks of very low-calorie 
diet in 54 healthy volunteers 
before 13 weeks of 
supplementation  
High or low doses 
High doses: 3.6 g·day of CLA or Placebo  
Low dose: 1.8 g·day of CLA or Placebo 
↔ EI at standardized breakfast 
↑ Fullness and satiety in CLA 
↓ Hunger in CLA 
↔ Weight regain 
Lambert et al. (2007) 
12 weeks supplementation in 
64 healthy volunteers 
3.9 g CLA capsule (65.9% CLA: 29.7% 
c9,t11; 30.9% t10,c12; 2.9% other 
isomers) 
3.9 g high-oleic acid sunflower oil 
(placebo) 
↔ Subjective sensations (fullness, appetite, 
satiety)  
Medina et al. (2000) 
64 days supplementation in 
17 healthy women 
3.9 g CLA (65% CLA: 22.6% t10,c12; 
23.6% c11,t13; 17.6% c9,t1; and 36.2% 
other isomers) 
3 g placebo (72.6% linoleic acid) 
Leptin initially ↓ but then returned to 
baseline in CLA 
↔ appetite, despite ↓ leptin 
Norris et al. (2009) 
36-week supplementation 
study in 55 obese 
postmenopausal women with 
T2D 
CLA: 8.0 g·day oil providing 6.4 g·day 
CLA (41.6% c9,t11 and 40.4% t10,c12 
isomers) and 1.6 g oleic/palmitic acids 
Placebo: 8.0 g·day oil providing 8.0 g·day 
safflower oil 
↓ BMI 
↔ EI (from self-reported diet diary data) 
↔ Leptin 
Pinkoski et al. (2006) 
7 weeks resistance training 
with supplementation in 76 
healthy men and women 
Placebo: 7 g·day sunflower oil 
CLA: Tablets containing ~66% CLA (of 
which 36.1% c9,t11 and 36.3% t10,c12 
isomers) providing 5 g·day 
↑ Lean tissue mass after CLA for 7 weeks 
↔ Self-assessed energy intake after the 
intervention period 
Wanders et al. (2007) 3-week supplementation Fed diet containing 14.6 g c9,t11 CLA and ↔ Self-assessed energy intake during the 
63 
 
study in 20 healthy subjects 3.3 g t10,c12 CLA, and 1.4 g other CLA 
isomers 
supplementation period 
Watras et al. (2007) 
6-month supplementation 
study 
Placebo: 4 g·day safflower oil 
CLA: 4 g·day of oil providing 3.2 g·day 
CLA (39.2% c9,t11 and 38.5% t10,c12) 
↓ Weight gain over the 6 month period in 
CLA 
↔ EI during EI, whilst EI ↑ in placebo 
CLA: Conjugated Linoleic Acid; EI: Energy Intake; CCK: Cholecystokinin; GIP: Gastric Inhibitory Peptide; PP: Pancreatic Polypeptide; BW: 
Body Weight. ↑ shows increased or greater ↓ shows decreased or lesser ↔ shows no change or difference. 
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Table 3. Studies on the effect of short-chain fatty acids on satiety 
Study Study Design Fat used Major Results 
Cani et al. (2006) 
2 x 2-week crossover with 
10 healthy subjects 
16 g·day oligofructose (OF) 
16 g·day placebo (PLA) 
Two-week washout between each. 
↑ satiety after breakfast with OF intake 
↓ intake at breakfast and lunch after 2 
weeks of OF 
↓ overall EI in OF 
Chambers et al. 
(2015) 
24 weeks parallel in 60 
subjects 
10 g·day inulin-propionate (IP) 
10 g·day of inulin-control (CON) 
↑ PYY and GLP-1 release after IP 
↓EI after IP by 14% 
↔ Subjective sensations 
Darwiche et al. 
(2001). 
Breakfast study in 9 healthy 
volunteers 
Control bread made with basic recipe, or 
same bread with the addition of sodium 
propionate  
↓ GE after bread containing propionate 
Darzi, Frost and 
Robertson (2012) 
Breakfast study in 20 healthy 
unrestrained eaters 
Sandwiches made with a propionate rich 
sourdough to yield 4.8 mmol propionate 
per 100 g of bread or a control 
equivalent  
↔ EI at ad lib lunch between trials 
↔ 24 h EI between trials 
↔ Appetite ratings 
Darzi et al. (2014) 
2 studies investigating the 
oral properties of SCFA 
Study 1:  
Control drink: 75g in 275g water across 
two drinks 
Unpalatable drink: 25g vinegar and 25g 
squash in 100g water followed by 50g 
squash in 100g water 
Palatable drink: 25g vinegar and 75g 
squash in 250g water across two drinks 
Study 2: 
Study 1: 
↑ Nausea after unpalatable drink 
↓ ad lib and 24 h EI after vinegar 
treatments 
 
Study 2: 
↓ Pleasantness after vinegar drink 
↔ Nausea ratings 
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Modified sham feeding of a control drink 
(180g water) or a vinegar drink (230g 
white wine vinegar in 150g water) 
↔ Appetite ratings 
↔ EI at ad lib meal 
Daud et al. (2014) 
6 weeks parallel in 22 
subjects 
30 g·day oligofructose (OF) 
30 g·day cellulose (CON) 
↑ acetate concentrations after OF 
↑ fasting serum propionate and butyrate 
after OF 
↑ PYY AUC after OF 
↑ GLP-1 AUC after CON 
↓ EI and hunger after OF 
Freeland et al. (2010) 
One year dietary 
modification to alter fibre 
intakes in 28 
hyperinsulinaemic 
volunteers 
Two groups: 
High-wheat fibre cereal (All Bran) 
Low-fibre cereal (Rice Krispies) 
↑ plasma butyrate and GLP-1 secretion 
after 9-12 months of high fibre intake  
Frost et al. (2014) Series of tests in mice  11C Acetate injections 
↓ EI 
↓ agouti-related peptide expression 
↑ proopiomelacocortin expression 
Hlebowicz et al. 
(2015) 
Crossover trial with 15 
healthy subjects 
28 mmol acetate soaked in different 
breads: 
White (W),  
Wholemeal (WM) 
Whole-kernel wheat (WK) 
Unsoaked white bread (CON) 
↑ satiety in WK 
↔ GE 
Jouët et al. (2013) Perfusion study in 20 healthy SCFA mixture: 66% acetic acid, 24% ↔ colonic motility  
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volunteers propionic acid, and 10% butyric acid 
Kondo et al. (2009) 
12 week parallel 
supplementation study in 
155 obese individuals  
0 mg/100 ml acetate (PLA) 
15 mg/100 ml acetate (LOW) 
30 mg/100 ml acetate (HIGH) 
↔ EI, macronutrient breakdown or EE 
Liljeberg and Björck 
(1998) 
Breakfast study with 12 
healthy volunteers 
Different breads baked to include lactic 
acid, sodium propionate or basic whole 
meal (as a control).  
↓ GE after bread containing propionate 
↑ satiety after bread containing propionate 
Mettler, Schwarz and 
Colombani (2009) 
Repeated measures study in 
27 subjects 
Milk rice meal with either: 
No additive (CON) 
4 g cinnamon (CIN) 
28 mmol acetate (ACE) 
Cinnamon and acetate (C&A) 
↔ satiety AUC 
↓ satiety 15-30 min post ingestion in C&A 
Nilsson et al. (2013) 
Crossover trial in 16 healthy 
adults 
Evening meal of Swedish brown beans 
(SBB) or white bread (WB), in portions to 
provide 35g of starch, given the night 
before a standardised breakfast. 
↑ PYY (51%) and oxyntomodulin after 
SBB 
↓ ghrelin after SBB (by 14%) 
↔ subjective sensations  
Ostman et al. (2005) 
Crossover trial with 12 
healthy subjects 
White bread (CON) 
With 18 mmol acetate (LOW) 
With 23 mmol acetate (MED) 
With 28 mmol acetate (HIGH) 
↑ satiety in HIGH: dose-response 
relationship 
Parnell and Reimer 
(2009) 
12-week supplementation in 
48 overweight/obese 
individuals 
21 g·day oligofructose (OF) 
21 g·day maltodextrin (PLA) 
↓ ghrelin after OF 
↑ PYY after OF 
↔ GIP and GLP-1 
↓EI after OF 
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Ruijschop et al. 
(2008) 
Preload study in 43 healthy 
women 
Non-fermented dairy beverage (placebo) 
Fermented dairy beverage 
Non-fermented beverage with the addition 
of 0.6% calcium propionate 
↑ fullness after fermented and non-
fermented beverage with addition of 
calcium propionate 
↔ Ad lib EI between all conditions 
Tarini and Wolver 
(2010) 
Acute feeding study in 12 
healthy participants 
Three test drinks: 
80g high fructose corn syrup 
56g high fructose corn syrup and 24g 
inulin 
56g high fructose corn syrup 
↑ serum SCFA concentrations after inulin 
ingestion 
↓ ghrelin after inulin 
↔ GIP and GLP-1 between inulin and 80g 
high fructose corn syrup drinks  
GE: Gastric emptying; EI: Energy Intake; EE: Energy Expenditure; BW: Body Weight; PYY: Peptide YY; GLP-1: Glucagon-Like Peptide 1; 
GIP: Gastric Inhibitory Peptide. ↑ shows increased or greater ↓ shows decreased or lesser ↔ shows no change or difference. 
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Table 4. Studies on the effect of diacylglycerol on satiety 
Study Study Design Fat used Major Results 
Kamphuis et al. 
(2003) 
Crossover trial with 12 
healthy women 
36h stay in respiration chamber where 
40% of fat came from DAG or TAG oil 
after 3 days of energy maintenance 
↑ satiety after DAG 
↑ β-oxidation 
Kawashima et al. 
(2008) 
1 year parallel trial in 
overweight or obese 
individuals  
Participants were given DAG or TAG oil 
to replace normal cooking oil. 
↓ EI in both groups 
Li et al. (2008)  
120 day parallel in 127 
individuals with T2D  
25 g·day diacylglycerol (DAG) 
25 g·day triacylglycerol (TAG) 
↓ CHO intake after DAG 
↓ EI (non-sig) after DAG 
↑ leptin after TAG  
Stoeckel et al. (2008) 
Acute study in 12 normal-
weight humans 
Control beverage: 21 kcal lipid free 
beverage 
Lipid beverage: made from 16 g ethyl 
oleate and 28g Enova oil which contains 
80% diglycerides and 20% triglycerides  
Participants stratified into high and low 
PYY responders. 
↑ Plasma PYY after lipid drink 
In high PYY responders, lipid beverage ↑ 
satiety 
No effect in low PYY group 
Yamamoto et al. 
(2001) 
12 week parallel trial in 16 
diabetic patients 
10 g·day diacylglycerol (DAG) 
10 g·day triacylglycerol (TAG) – normal 
cooking oil 
↔ EI (from self-reported diet diary data) 
DAG: Diacylglycerol; TAG: Triacylglycerol; GE: Gastric emptying; EI: Energy Intake; EE: Energy Expenditure; BW: Body Weight; PYY: 
Peptide YY; GLP-1: Glucagon-Like Peptide 1; GIP: Gastric Inhibitory Peptide; CHO: carbohydrate. ↑ shows increased or greater ↓ shows 
decreased or lesser ↔ shows no change or difference. 
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Table 5. Studies on the effect of omega-3 polyunsaturated acids on satiety 
Study Study Design Fat used Major Results 
Bruera et al. (2003) 
2-week high-dose 
supplementation study in 
patients with cancer cachexia 
Control: 1000 mg·day olive oil 
Intervention: 1000 mg·day fish oil 
(providing 180 mg EPA and 120 mg 
DHA) 
↔ change in appetite after 2 weeks 
supplementation 
Damnsbo-Svendsen, 
Rønsholdt and 
Lauritzen (2013) 
3 weeks supplementation in 
healthy individuals 
Control: 10 soybean tablets a day 
providing a total of 5.2 g soybean oil 
Intervention: 10 fish oil tablets a day 
providing a total of 3.5 g n-3 PUFA, of 
which 1.9g was EPA and 1.1g was DHA 
↑ appetite and ↓ postprandial fullness after 
fish oil supplementation 
Jatoi et al. (2004) 
An international clinical trial 
involving supplementation in 
421 patients with cancer. 
Median study involvement 
of volunteers was “slightly 
more than 3 months” 
Supplementation was as follows: 
1.09 g of EPA and 0.46 g of DHA a day 
600 mg·day megestrol acetate 
Or a combination of the two 
↔ appetite improvement in all three groups 
Parra et al. (2008) 
Supplementation of during 
the last phase of a weight 
loss program in overweight 
and obese individuals 
4 diets 
Control: no seafood, 6 placebo capsules a 
day 
Lean fish: 150 g cod 3 times a week 
Fatty fish: 150 g salmon 3 times a week 
Fish oil supplementation: 6 capsules a day 
 
The two low n-3 PUFA provided > 260 
mg·day n-3 fatty acids. 
The two high n-3 PUFA provided > 1300 
↑ fullness in high n-3 groups 
↓hunger and desire to eat in high n-3 
groups 
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mg·day n-3 fatty acids.  
Yehunda, Rabinovitz 
and Mostofsky 
(2005) 
3-week supplementation 
study in students  
33 students in control group received a 
placebo “mineral oil” 
88 students took Awake (TransCulture, 
Japan tables containing n-3 and n-6 in a 
ratio of 1:4 
↑ appetite after supplementation with the 
mixture of lipids 
Zaid et al. (2012) 
8-week supplementation 
study in 51 children with 
leukaemia 
2 groups: 
Control group that received individualised 
dietary advice 
Trial group that received individualised 
dietary advice alongside fish oil 
supplementation: 
1 x 1200 mg capsule per day containing 
360 mg EPA and 240 mg DHA 
↑ appetite in children with leukaemia 
↑ energy intake over control group 
  
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; PUFA: polyunsaturated fatty acids. ↑ shows increased or greater ↓ shows decreased 
or lesser ↔ shows no change or difference. 
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Table 6. Studies on the effect of small particle lipids on satiety 
Study Study Design Fat used Major Results 
Burns et al. (2000) 
Acute feeding study in two 
groups of 30 volunteers 
Control: Yoghurt containing 6 g dairy fat 
Test: Yoghurt containing 5 g OlibraTM and 
1 g dairy fat 
↓ Energy intake, food intake, and intake of 
all macronutrients after test food at 4 h 
↔ subjective sensations of appetite and 
hunger 
Burns et al. (2001) 
Breakfast study in healthy 
weight, overweight and 
obese participants 
Control: Yoghurt containing 6 g dairy fat 
Test: Yoghurt containing 5 g OlibraTM and 
1 g dairy fat 
↓ fat, carbohydrate, protein and total energy 
intake at both 4 h and 8 h after test 
infusion across all groups 
↔ Obese intake at 4 h  
↓ Obese intake at 8 h 
↔ subjective sensations of appetite and 
hunger 
Burns et al. (2002) 
Breakfast study in 50 healthy 
individuals 
Yoghurt with varying doses of OlibraTM: 
0g (control), 5 g, 10 g, or 15 g. 5 and 10 
g amounts also had 10 and 5 g of milk 
fat, respectively, whereas the control 
was 15 g of milk fat.  
↑ suppression with food intake as dose of 
OlibraTM increased 
↔ subjective sensations of appetite and 
hunger 
Chan et al. (2012) 
Acute crossover feeding 
study 
4.2 g lipids from a control or 15 g of 
FabulessTM provided in (or alongside) 
liquid form, semi-solid form and solid 
form, with a control for each state: 
Liquid emulsion (LE) 
Liquid control (LC) 
Semi-solid emulsion (LE + Yoghurt) 
Semi-solid control (LC + Yoghurt) 
Solid emulsion (LE + Muffin) 
↑ fullness after LE + Yoghurt, no effect of 
FabulessTM in liquid or solid form 
↔ EI across all conditions 
72 
 
Solid control (LC + Muffin) 
Chan et al. (2017) 
Acute crossover feeding 
study 
6 conditions, 4 lipids and 2 controls: 
FabulessTM emulsion 
Dairy emulsion with dairy emulsifier 
Dairy emulsion with soy lecithin 
emulsifier  
Dairy control (non-emulsified) 
Palmolein emulsion with dairy emulsifier 
Palmolein control (non-emulsified)  
↔ satiety ratings between lipids and 
respective controls 
↔ EI between lipids and respective 
controls 
Diepvens et al. 
(2007) 
18-week weight maintenance 
and dietary manipulation in 
50 overweight women 
Control: 500 g of yoghurt containing 10 g 
milk fat, split into 2 doses 
Test: 500 g of yoghurt containing 6 g milk 
fat and 4 g vegetable fat from OlibraTM, 
split into 2 doses 
↓ hunger after test product  
↑ CCK, GLP-1, and βHB after test product 
↓ weight regain after test product 
Hussein et al. (2014) 
Crossover feeding study in 
11 healthy people 
3 emulsions: 
Control: Coarse emulsion (6 μm droplets) 
Coarse+LBG: Coarse emulsion (6 μm 
droplets) + 0.5% locust bean gum 
Fine+LBG: Fine emulsion (0.4 μm 
droplets) + 0.5% locust bean gum 
↓ GE after LBG, of which Fine+LBG ↓ the 
most 
↑ CCK after both LBG trials, no diff 
between Coarse+LBG and Fine+LBG 
↓ EI after both LBG trials, greater ↓ after 
Fine+LBG compared to Coarse+LBG  
↔ VAS 
Knutson et al. (2010) Intragastric perfusion study 
Control: 300 g of yoghurt containing 8.5 g 
dairy fat 
Test: 300g of yoghurt containing 8.5 g of 
FabulessTM emulsion 
↑ Lipids remaining in the jejunum after test 
perfusion 
↓ GE after test perfusion 
Ledeboer et al. 
Randomised crossover study 
involving intraduodenal 
Control: Saline with emulsifier ↑ CCK release and gallbladder contraction 
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(1999) infusion study in 6 healthy 
men 
Emulsion trial: Emulsified soybean oil 
Non-emulsion trial: Non-emulsified 
soybean oil 
after emulsified LCT 
↔ Emulsifier in saline and non-emulsified 
LCT  
Logan et al. (2006) 
Crossover dietary 
manipulation study  
Control: 5 g milk fat  
Test: 12.5 OlibraTM providing 5 g fat 
↔ EI across trials  
↔ on subjective sensations across trials 
Marciani et al. (2009) 
Acute feeding study with 
specially designed lipid 
emulsions 
Emulsions made from [13C]palmitate-
enriched olive oil, providing 50 g of fat 
in 3.6 μm droplets. Two conditions were 
‘acid-stable’ and ‘acid-unstable’ 
emulsions 
↑ GE in acid-unstable emulsion 
↓ ratings of hunger and appetite after acid-
stable emulsion 
Ohlsson et al. (2014) Two acute feeding studies 
Three doses of lipids from yoghurt 
(control) or fractionated oat oil (LOO): 
1.8 g, 14 g, and 35 g 
↑ satiety after LOO in women but not men 
↑ GLP-1, PYY and CCK after 14 g and 35 
g of LOO 
↔ EI across trials 
Peters et al. (2014) Acute feeding study 
Fat-free drink with: 
5g fat in 3 μm droplets 
9g fat in 3 μm droplets 
5g fat in 0.1 μm droplets 
9g fat in 0.1 μm droplets 
↔ EI across all trials 
↑ CCK release in smaller droplet trial, but 
only in 9 g fat load 
Rebello et al. (2012) 
12-week dietary 
supplementation study 
Control group: yoghurt providing 1.95 g 
milk fat twice daily 
Test group: yoghurt providing 2.1 g 
OlibraTM twice daily 
↓ hunger after OlibraTM supplementation 
↔ EI and ratings of appetite and satiety 
between trials 
Seimon et al. (2009) 
Randomised crossover study 
involving intraduodenal 
infusion study in 10 healthy 
men 
Control: Saline 
0.26 μm droplet infusion:  
 Intralipid (Fresenius Medical Care 
↑ CCK and PYY release after 0.26 μm 
droplet infusion 
↓ hunger after 0.26 μm droplet infusion 
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Australia) 
30 μm: Tween 80, water and canola oil  
170 μm: Tween 80, water and canola oil 
Smit et al. (2011) 
Breakfast study in 24 healthy 
volunteers 
Test drinks with 5 g milk/corn fat added 
(‘Control’) or 12.5 g of FabulessTM 
(containing 5 g of fat) added: 
During the manufacturing process 
(‘Processed’) 
After the manufacturing process 
(‘Unprocessed’) 
↔ In EI at ad lib lunch 
↓ In EI at ad lib dinner after Unprocessed  
↔ on subjective sensations across trials 
Smit et al. (2012) 
Breakfast and preload study 
comprising of 2 separate 
studies 
100 g test drinks comprising of: 
2.0g added milk fat 
2.0g added fat from 5 g FabulessTM 
3.2 g added milk fat 
3.2 g added fat from 8 g FabulessTM  
↔ energy intake and subjective sensations 
of satiety when comparing each dose to 
the control 
↑ hunger at one timepoint after the 
FabulessTM drink, no other differences 
↑ EI at one timepoint after the FabulessTM 
drink, no other differences 
EI: Energy Intake; GE: Gastric Emptying; VAS: Visual Analogue Scale; CCK: Cholecystokinin, GLP-1: Glucagon-Like Peptide 1; βHB: β-
Hydroxybutyrate. ↑ shows increased or greater ↓ shows decreased or lesser ↔ shows no change or difference. 
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Table 7. Summary of the advantages and disadvantages of the functional lipids discussed within this review.  
Advantages Disadvantages 
Medium chain triglycerides 
• Strong potential to mediate satiety(Coleman, Quinn, and 
Clegg 2016; Rolls et al. 1988; Van Wymelbeke et al. 1998; 
Van Wymelbeke, Louis-Sylvestre, and Fantino 2001). 
• Safe for consumption. 
• Possible for effects to be additive with other satiating foods 
due to hormone-independent effects(Miriam E Clegg 2010). 
• Can beneficially alter body composition without altering 
appetite or satiety(Krotkiewski 2001). 
• Repulsive taste, ecological validity possibly 
questionable(Miriam E Clegg 2010).  
• Can cause nausea when ingested in high 
amounts(Jeukendrup et al. 1998; Goedecke et al. 2005). 
 
Conjugated Linoleic Acid 
• Only one study investigating the acute use of CLA on satiety 
found it suppressed hunger compared to a control oil, even in 
small amounts(Coleman, Quinn, and Clegg 2016). 
• Satiety-independent effects on weight loss(Blankson et al. 
2000; Belury, Mahon, and Banni 2003; Gaullier et al. 2007).  
• Chronic studies indicate no effect on satiety(Blankson et al. 
2000; Belury, Mahon, and Banni 2003; Gaullier et al. 2007). 
• Lack of short-term data investigating effects regarding 
appetite, more studies needed to draw conclusions.  
• Possible deleterious effects related to insulin 
resistance(Medina et al. 2000; Ulf Risérus et al. 2002; 
Smedman and Vessby 2001).  
Short Chain Fatty Acids 
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• Various mechanisms by which SCFA can regulate satiety, 
including stimulation of satiety hormones(Psichas et al. 2014; 
Tolhurst et al. 2012; Samuel et al. 2008), intestinal 
gluconeogenesis(Bienenstock, Kunze, and Forsythe 2015b; 
De Vadder et al. 2014) and gastric emptying. Could possibly 
be additive with other functional lipids or foods with satiating 
properties(Liljeberg and Björck 1996; Darwiche et al. 2001). 
 
• Mode of delivery varies between studies, so the 
determination of the effects of each different mode is 
difficult. 
• Many confounding factors, effects reported previously 
possibly not due to SCFA(J Darzi, Frost, and Robertson 
2012; J Darzi et al. 2014). 
• Low tolerability and palatability of acetate means effects are 
not necessarily related to satiety(J Darzi et al. 2014).  
• No study to date has investigated the oral delivery of 
butyrate, no data on its effects.  
Diacylglycerol 
• Potentially cumulative mechanisms which, in theory, could 
result in a strong satiety signal.  
• Shown to be effective when replacing other fats in the diet in 
an ad libitum protocol. Beneficial as DAG does not require 
set doses to elicit its effects(Kawashima et al. 2008).  
• DAG used in previous studies no longer in production, and 
to the knowledge of the author, there is currently no other 
available source. Until another DAG is produced, this, 
unfortunately, does not seem a feasible avenue of research. 
• No chronic adaptation; must be used repeatedly for repeated 
acute effects(Yamamoto et al. 2001). 
n-3 PUFA 
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• Possibly as good as a steroidal treatment in increasing cancer 
patients’ energy intakes in an attempt to reverse 
cachexia(Bruera et al. 2003; M D Barber et al. 1999; Jatoi et 
al. 2004).  
• Widely available. 
• Possibly needs supplementation to induce effects, no acute 
effect. 
• Various fish oil supplements commercially, with various 
concentrations and ratios of EPA:DHA, and some may be 
more beneficial than others.  
Small particle lipid emulsions 
• Possible decrease in hunger when supplementing with 
FabulessTM(Burns et al. 2001, 2000, 2002), but most studies 
do not corroborate this(H. J. Smit et al. 2012; Y.-K. Chan et 
al. 2012).  
• Strong evidence that droplet size can be linked to the ileal 
brake(Knutson et al. 2010; Hussein et al. 2015; Seimon et al. 
2009).  
• The only commercially available SPL has little evidence of 
its efficaciousness(H. J. Smit et al. 2012; Y.-K. Chan et al. 
2012), other SPL are manufactured specifically for studies. 
• A suitable emulsion still needs developing.  
• Evidence supporting droplet size and the ileal brake focuses 
mainly on the intragastric administration of the SPL which 
are not feasible methods of increasing satiety.  
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